Abstract:Introduction: Patient-derived organoids (PDOs) enable the ex vivo study of tumor heterogeneity and its effect on response to treatment. Our previous work demonstrated that our robust pan-cancer organoid platform shows genetic and transcriptomic concordance with clinical tumor samples and can be deployed for high-throughput drug response screening. Here, we ran a standard of care (SOC) panel on PDOs with paired de-identified clinically curated data to enable a comparison of patient response to the same drugs ex vivo and exploration of potentially more effective treatment alternatives. Methods: Patient tumor samples were cultivated into tumor PDOs in extracellular matrix + chemically defined media. PDOs underwent pathological review to ensure development of malignant tissue. PDOs were identified by clusters of Hoechst-positive cells and live and dead cell counts for each PDO were determined using fluorescent stains. The median number of cells per PDO in the well was calculated, excluding PDOs with <3 cells and the top 1% of PDOs by area. Drug screens were run with 6 doses of the compound and the inverse area under the curve of ToPro3 live cell measurements was calculated to quantify response. Tempus xT DNA-seq and xR whole-transcriptome assays were used to perform NGS on organoids and patient samples where available. Data was processed through our standard pipeline to identify targetable mutations, neoantigens, copy number variants (CNVs) and fusions. Results: We analyzed 38 PDOs with paired patient data across 9 different cancer types comprising mostly lung (n=14) and colorectal (n=12); 17 PDOs had responses associated with treatment given close to the biopsy collection date. Across the full PDO cohort, we observed a range of responses to SOC compounds, providing a platform to better understand biomarkers and mechanisms of response. Treatment response in PDOs correlated with patient response in many cases. In the 3 patients with progression-free survival >1 year and outcomes of either complete response or stable disease, all showed strong responses to the corresponding drugs in the SOC panel. For most patients with progressive disease recorded after treatment the corresponding PDO cluster showed limited response to treatment. The SOC panel includes several targeted therapies that provide insight into how patients respond to treatment beyond chemotherapy. For two patients with limited response to treatment in both patient and PDO, we identified targeted therapies relevant to their clinico-genomic landscape. One patient showed improved clinical outcomes to a later line of therapy with a similar mechanism of action to the drug that showed response in the organoid. Conclusion: These results suggest that PDOs may serve as a powerful tool for predicting patient response to treatment and aid the development of new therapies. Citation Format: Kathleen A. Burke, Brian Larsen, Yi-Hung Carol Tan, Jessica Barbeau, Curtis Brinkman, Elle Moore, Nick Callamaras, Jonathan R. Dry, Iker Huerga, Kate Sasser, Jeffrey A. Borgia. Integration of patient-derived tumor organoids and patient clinical multimodal data to investigate the role of organoids in predicting treatment response [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 225.

Establishment of patient‐derived organoids for guiding personalized therapies in breast cancer patients

Patient-derived 3D Bioprinting Pan-Cancer Drug Screening Platform for Personalized Medicine.

Patient‐Derived Organoids Can Guide Personalized‐Therapies for Patients with Advanced Breast Cancer

The combination of breast cancer PDO and mini‐PDX platform for drug screening and individualized treatment

Patient-derived organoids: a promising tool for breast cancer research

Successful Patient-Derived Organoid Culture of Gynecologic Cancers for Disease Modeling and Drug Sensitivity Testing

The Establishment of Patient-Derived Organoid Models and Drug Response of Resectable Non-Small Cell Lung Cancer

Creation and Development of Patient-Derived Organoids for Therapeutic Screening in Solid Cancer

Patient-derived organoids in precision cancer medicine

Patient-derived organoid culture of gastric cancer for disease modeling and drug sensitivity testing

Genomic characteristics and drug screening among organoids derived fromnon-small celllung cancer patients

Ovarian Cancer Patient-Derived Organoids Used as a Model for Replicating Genetic Characteristics and Testing Drug Responsiveness: A Preliminary Study

Abstract 2073: Human breast patient derived organoids: Development and characterization of a new tissue mimetic model

Gastric cancer patient-derived organoids model for the therapeutic drug screening

Patient-derived organoids as a platform for drug screening in metastatic colorectal cancer

The future of cancer therapy: exploring the potential of patient-derived organoids in drug development

Clinical efficacy of tumor organoid‐guided cancer therapy for locally advanced unresectable or metastatic breast cancer

389PThe establishment of patient-derived organoid models and drug response of resectable non-small cell lung cancer

Abstract 225: Integration of patient-derived tumor organoids and patient clinical multimodal data to investigate the role of organoids in predicting treatment response

Organoids from patient biopsy samples can predict the response of BC patients to neoadjuvant chemotherapy

Patient‐derived Cancer Organoids for Drug Screening: Basic Technology and Clinical Application